HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free All Versions of this Article: fj.07-087924v1 fj.07-087924v2 22/6/1635    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gong, Z. Articles by Niklason, L. E. Search for Related Content PubMed PubMed Citation Articles by Gong, Z. Articles by Niklason, L. E.

Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs)

Department of Anesthesiology, Yale University Medical Center, New Haven, Connecticut, USA

¹Correspondence: Vascular Biology and Transplantation, Yale School of Medicine, P.O. Box 208089, New Haven, CT 06520-8089, USA. E-mail: laura.niklason{at}yale.edu

Using biodegradable scaffold and a biomimetic perfusion system, our lab has successfully engineered small-diameter vessel grafts using endothelial cells (ECs) and smooth muscle cells (SMCs) obtained from vessels in various species. However, translating this technique into humans has presented tremendous obstacles due to species and age differences. SMCs from elderly persons have limited proliferative capacity and a reduction in collagen production, which impair the mechanical strength of engineered vessels. As an alternative cell source, adult human bone marrow-derived mesenchymal stem cells (hMSCs) were studied for their ability to differentiate into SMCs in culture plates as well as in a bioreactor system. In the former setting, immunofluorescence staining showed that MSCs, after induction for 14 days, expressed smooth muscle -actin (SMA) and calponin, early and mid-SMC phenotypic markers, respectively. In the latter setting, vessel walls were constructed with MSC-derived SMCs. Various factors (i.e., matrix proteins, soluble factors, and cyclic strain) in the engineering system were further investigated for their effects on hMSC cell proliferation and differentiation into SMCs. Based on a screening of multiple factors, the engineering system was optimized by dividing the vessel culture into proliferation and differentiation phases. The vessel walls engineered under the optimized conditions were examined histologically and molecularly, and found to be substantially similar to native vessels. In conclusion, bone marrow-derived hMSCs can serve as a new cell source of SMCs in vessel engineering. Optimization of the culture conditions to drive SMC differentiation and matrix production significantly improved the quality of the hMSC-derived engineered vessel wall.—Gong, Z., Niklason, L. E. Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs).

Key Words: smooth muscle cell • bioreactor • cyclic strain • extracellular matrix • soluble factors

This article has been cited by other articles:

				J. Han, J. Y. Liu, D. D. Swartz, and S. T. Andreadis Molecular and functional effects of organismal ageing on smooth muscle cells derived from bone marrow mesenchymal stem cells Cardiovasc Res, March 3, 2010; (2010) cvq024v2. [Abstract] [Full Text] [PDF]

				S.H. Zaky and R. Cancedda Engineering Craniofacial Structures: Facing the Challenge Journal of Dental Research, December 1, 2009; 88(12): 1077 - 1091. [Abstract] [Full Text] [PDF]